

Molecular Mechanism of Caffeine-Aspirin Interaction in Kopi Balur 1 as Anti-Inflammatory Agent: A Computational Study

Viol Dhea Kharisma^{1,2}, Arif Nur Muhammad Ansori^{2,3}, Amaq Fadholly³, Teguh Hari Sucipto⁴

¹Master Student, Master Program in Biology, Department of Biology, Faculty of Mathematic and Natural Sciences, Universitas Brawijaya, Malang, Indonesia, ²Researcher, Division of Genetics and Molecular Biology, Generasi Biologi Indonesia Foundation, Gresik, Indonesia, ³Doctoral Student, Doctoral Program in Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia, ⁴Researcher, Dengue Study Group, Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia

Abstract

Balur treatment (BT) is a method that works to remove toxins in the form of free radicals released via the skin. One of the remedies used is Kopi Balur 1 (KB1) which contains aspirin and caffeine used during the BT, so that KB1 is believed to have the potential to reduce or inhibit the occurrence of inflammatory processes in the body. Therefore, we investigate the interactions that occur between ligands and proteins, predict the action mode of caffeine-aspirin contained in KB1 as an anti-inflammatory agent, and modeling the 3D structure of pro-inflammatory proteins in the human body. The target compound, aspirin-caffein, was obtained from a database, then used to identify the pathway on the STITCH webserver, then the target protein was obtained and modeled in 3D using the SWISS-MODEL webserver, and the structures obtained were represented in PyMol software. In sum, the aspirin-caffeine ligand complex contained in KB1 has the potential as an anti-inflammatory agent in the human body via the molecular mechanism of binding and inhibiting the biological activity of proinflammatory proteins, i.e. PTGS1, PTGS2, and ADOR2A.

Keywords: *Anti-inflammatory agent, computational study, kopi balur 1, molecular mechanism.*

Introduction

Balur treatment (BT) is a method used to remove toxins in the form of free radicals contained in the human body. Balur is a treatment method from the Javanese society that has been developed to improve the quality of life. BT uses natural ingredients as free radical scavenging and components of aromatic chemical compounds such as amino acids and other aromatic compounds. The body of a person undergoing BT must lie on a copper plate and this therapy is believed to have the potential to reduce or inhibit the effects of inflammation in the body¹.

Caffeine is a type of heterocyclic alkaloid in the methylxanthine group, and by definition means

organic compounds containing nitrogens with a two-ring structure. This molecule naturally occurs in many types of plants as secondary metabolic. Caffeine is a compound belonging to the xanthine derivative alkaloids that contain a methyl group. Caffeine has long been obtained from plant extracts such as coffee beans, tea, and chocolate². In addition, Indonesia possesses a vast biodiversity with a high number of potential natural medicinal sources^{3,4}.

On the other hand, aspirin or acetylsalicylic acid (acetosal) is a type of drug that is often used as an analgesic, antipyretic, and anti-inflammatory. Aspirin can also be used in low doses for a long period of time to prevent heart attacks. Aspirin is made by esterification, in which the active ingredient of aspirin is reacted with anhydrous acetic acid and glacial acetic acid. In the process of making this esterification reaction, it is assisted by an acid catalyst to speed up the reaction⁵.

Corresponding author:

Teguh Hari Sucipto

Email: teguhharisucipto@staf.unair.ac.id

Inflammation is an immune response to the local tissue caused by injury or damage caused by certain factors, which function to destroy, reduce infectious agents that damage the tissue or play a role in the regeneration process of the injured tissue^{6,7}. Therefore, we investigate the interactions that occur between ligands and proteins, predict the action mode of caffeine-aspirin contained in KBI as an anti-inflammatory agent, and modeling the 3D structure of proinflammatory proteins in the human body.

Materials and Methods

Sample Preparation

This study conducted at Department of Biology, Faculty of Mathematic and Natural Sciences, Universitas Brawijaya, Indonesia. This study used aspirin (ID 2244) and caffeine (ID 2519) in the form of 3D structures (structure data format or sdf) and canonical SMILES obtained from the PubChem database (pubchem.ncbi.nlm.nih.gov). Pubchem is a specific database that stores information related to organic chemical compounds, synthesis, and certain substances and is a branch of NCBI. A sample of chemical compounds originating from PubChem are in the form of 3D and 2D structures⁸.

Drug-Likeness Prediction

Samples of target compounds were tested for their potential as drug molecules by checking their accuracy according to Lipinski's rules^{9,10}. The structure of 3D compounds in the sdf format was analyzed on the Lipinski webserver (scfbio-iitd.res.in/software/drugdesign/lipinski.jsp) and the results were identified which consisted of molecular weight, hydrogen acceptor donors, lipophilicity, and molar refractivity.

Pathway Analysis

The interaction between aspirin-caffeine and the target protein in the human body can be identified on STITCH (stitch.embl.de). STITCH is a webserver whose role is to predict the interaction of a chemical compound in the target organism, which will get stronger association scores based on a database or evidence from experiments that have been carried out¹¹.

Protein Modeling and Validation

Protein sequences contributing to the inflammatory

response were obtained from the Uniprot database (uniprot.org), then modeling via the SWISS MODEL webserver (swissmodel.expasy.org), and the results of the modeling were identified by Ramachandran plot. The modeling used in this research is homology and works based on the availability of templates in the database to produce a target protein model^{8,12}. The quality of the model is identified via a plot that works based on the position of specific amino acids that will determine the favored score on the model¹³.

Result and Discussion

Molecular Interaction of Caffeine-Aspirin with Proteins in Human Body

Based on the results of *in silico* analysis of the interaction between ligand-protein on the STITCH webserver, caffeine (ID 2519) have a canonical SMILES CN1C=NC2=C1C(=O)N(C(=O)N2C)C and aspirin (ID 2244) have a canonical SMILES CC(=O)OC1=CC=CC=C1C(=O)O, most likely interact with 10 proteins inside the body of *Homo sapiens*. The results of identifying the interaction of aspirin-caffeine with 10 proteins in the body of *Homo sapiens* showed that all of them are the highest evidence because they have a score of above 0.900 or 90.0%. In STITCH, there are a number of edge convention scores starting from low (0.150), medium (0.400), high (0.700), and highest confidence (0.900)¹¹. So, the greater the score, the stronger of the suspicion of interaction occurs when the caffeine aspirin ligand complex is in the body of *Homo sapiens*.

Based on the identification of the interaction between the aspirin-caffeine ligand complexes with the target protein, there are also target proteins that contribute to the inflammatory mechanism in the human body, such as PTGS1 and PTGS2 (interact with aspirin) and ADORA2A (interact with caffeine). Carrol *et al.* have explained that PTGS1 can increase the production of mucus layers on the inside of the stomach, making other contributions such as reducing stomach acid levels¹⁴. PTGS1 is often found in areas where there are inflammatory mechanisms, although digestive tract organs are also found¹⁵. Consequently, most likely when aspirin is in the human body, it will interact with the PTGS1 receptor.

ADORA2A is a type of adenosine receptor^{16,17}. A2A receptors can be found throughout the body and are present on the surface of immunocompetence cells. These receptors have an important role in the inflammatory process (anti-inflammatory agent)⁶. Thus, when caffeine is in the human body, it is likely that caffeine will interact with the ADORA2A receptor. The results of the

STITCH analysis in the form of a complex interaction of aspirin-caffeine molecules with target proteins in the human body, are displayed in the form of shells which have several lines connecting between one another. Proteins with colored boxes are proinflammatory agents in the human body (Figure 1).




Figure 1. The molecular pathway of the aspirin-caffeine complex with proteins in the human body. The lines show the interactions of proteins (gray), ligands (green), and ligands (red).

Action Mode of Aspirin-Caffeine as Antiinflammatory Agent

Aspirin and caffeine are identified in relation to drug-likeness to determine whether the compound can be categorized as a drug molecule that refers to the five Lipinski rules. We predicted that the aspirin compound has a molecular weight of 180.000 D, high lipophilicity 1.310, one hydrogen bond donor, four hydrogen bond acceptors, molar refractivity 44.710, whereas for caffeine

it has a molecular weight of 194.000 D, high lipophilicity 0.061, 0 hydrogen bond donor, five hydrogen bond acceptor, and molar refractivity 49.100. Lipinski’s rules explain that a compound can be categorized as a drug molecule because it fulfills at least two rules, here are the rules of molecular weight ≤ 500 D, high lipophilicity ≤ 5 , hydrogen bond donors ≤ 5 , hydrogen bond acceptors ≤ 10 , and molar refractivity 40-130^{9,10}. Thus, aspirin and caffeine are categorized as drugs because they meet all five Lipinski’s rules.

Table 1. Drug-likeness test of aspirin and caffeine.

Compound	Lipinski Rules				
	MM (D)	LOGP	HBD	HBA	MR
Aspirin	180.000	1.310	1	4	44.710
Caffeine	194.000	0.061	0	5	49.100

Note: MM: Molecular mass; LOGP: High lipophilicity; HBD: Hydrogen bond donors; HBA: Hydrogen bond acceptors; MR: Molar refractivity.

After obtaining Lipinski results, aspirin and caffeine compounds were re-identified, the prediction of the action or the complex interaction of the ligand when inside the human body via STITCH webserver. This can produce information related to the nature of the molecular interactions that occur in the query ligand with the target protein, usually in the form of information on binding, activation, expression, and inhibition^{11,18}. Thus, it can be seen the type of action mode of the two query compounds, with the detected properties marked using the sign (√). There are five target proteins whose activity can be inhibited by the aspirin-caffeine ligand complex using direct binding, these proteins include PTGS1, PTGS2, CYP1A2, ADORA2A, and ATM (Table 2). In this study, we revealed that the aspirin-caffeine ligand complex has an action mode to be an anti-inflammatory agent by binding directly to the target proteins such as PTGS1, PTGS2, and PTGS3.

Table 2. The interaction of aspirin-caffeine ligand complex in the target protein.

Compound	Target Protein	Binding	Inhibition
Aspirin-Caffeine	PTGS1	√	√
	PTGS2	√	√
	CYP1A2	√	√
	ADORA2A	√	√
	CRP	-	√
	SELP	-	√
	ATM	√	√
	TBXA2R	-	√
	CHEK1	-	√
	CYP1A1	√	-

The 3D Model of Pro-Inflammatory Agent

Based on the analysis of previous stages, it is known that there are three proteins that play an important role in the occurrence of inflammatory mechanisms in the human body, PTGS1, PTGS2, and ADORA2A. The structure of three target proteins is modeled on the SWISS-MODEL webserver using a homology modeling method that has the principle of modeling based on query sequence alignment with a template in the database¹⁹. If there are more templates available in the database, the resulting

model is increasingly homologous, the modeling results also show a score, which must be above 20% in order to be called identical to the template^{12,20}. After obtaining the protein structure of the model, the quality of the model is identified again, which refers to a minimum favored region score of 80%, so that the model can be said to be valid¹³. Before doing the modeling, the sequences of the three target proteins in the FASTA format that were successfully obtained from the Uniprot database can be seen in Figure 2.

```
>sp|P23219|PGH1_HUMAN Prostaglandin G/H synthase 1 OS=Homo sapiens OX=9606 GN=PTGS1 PE=1 SV=2
MSRSLLLNLFLFLLLPPLVLLADPGAPTVPNPPCCYYPQHQGICVRFGLDRYQCDCTR
TGYSGNCTIPGLWTLNLSLRPSPSFTHFLLLTHGRWFMEFVNATFIREMLRMLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTMGTGKQKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHYGDNLERQ
YQLRLFKDGLLKYQLVDGEMYPSSVEEAPVLMHYPRGIPPSQMAVQGEVFGLLPGLMLY
ATLMLREHNRVCDLLKAEHPTWGDEQLFQTRRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFYRNRIAMEFNHLYHMHPLMPDSFKVGSQEYSYQFLFNTSMLVDYGVGA
LVDAFSRQIAGRIGGGRNMDHHLHVAVDVIRESEMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEEYGDIDALEFYPLGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYHKPSTFGGEVGFNIVKATLKKLVCLNTKTCYVVSFRVPDASQDDGPAVERPSTEL
```

A

```
>sp|P35354|PGH2_HUMAN Prostaglandin G/H synthase 2 OS=Homo sapiens OX=9606 GN=PTGS2 PE=1 SV=2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMVSGFDQYKCDCTRRTGFYGENCSTPEFL
TRIKLFLKPTNTVHYILTHFKGFMMVWNIPIFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSMFAFNNLSYYTRALPPVPDDCPTPLGVKQKQLPDSNEIVEKLLLRKFIPOQGS
NMMFAFFAQHFTHQFFKTDHKRGPFTNGLGHGVDLNIHYGETLARQKRLRLFKDGKMKY
QIIDGEMYPPTVKDQAEIYPPQVPEHLRFVAVQGEVFGVLPGLMNYATIWLREHNRVCD
VLKQHEPENGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPPELLFNKQFQVQ
NRIAAEFNTLYHMHPLLPDTFQIHQKYNQQFIYNSILLEGITQFVESFRQIAGRV
AGGRNPPAVQKVSQASIDQSRQMKYQSFNEYRKRFLMKPYESFEELTGEKEMSAELEAL
YGDIDAVEYLPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYHKPSTFGGEV
GFQIINTASIQSLICNWKGCPTFSVDPPELIKVTIINASSRSGLDDINPTVLLKER
STEL
```

B

```
>sp|P29274|AA2AR_HUMAN Adenosine receptor A2a OS=Homo sapiens OX=9606 GN=ADORA2A PE=1 SV=2
MPIMGSSVYITVELAIAVLAILGNVLVCHAVMLNSNLQWNTNYFVVSAAADIAGVLAIAI
PFAITISTGFCACACHGLFIACFVVLVTQSSIFSLLAIAIDRYAIAIRIPLRYMLVGTGR
AKGIIAICWLSFAIIGLTPMLGMINCGQPKEGKNHSQCGGEGVACLFEVDPVNNYMYF
NFFACVVLVPLLLMLGVYLRIFLAARRQLKQMESQPLGERARSTLQKEVHAAKSLAIIVG
LFALCNLPLHIINCFTFFCPDCSHAPLWMLYLAIVLSHTNSVWNPFIYAYRIREFRQTFR
KIIRSHVLROQEPFKAAGTSARVLAHGSQGEQVSLRLNGHPPGVWANGSAPHERRPNG
YALGLVSGGSAQESQNTGLPQVVELLSHELKGVCEPPGLDDPLAQDQAGVVS
```

C

Figure 2. The target protein sequences were obtained from the Uniprot database in FASTA format. (A) PTGS1, (B) PTGS2, and (C) ADORA2A.

PTGS1 protein sequence sample (ID P23219) has a length of around 599-mer, 92.88% identified as similar to the template, and 96.64% favored region, PTGS2 protein sequence (ID P35354) has a length of around 604-mer, 100% identified as similar with a template, and 97.09% favored region, the ADORA2A protein sequence has a sequence length of around 412-mer, 98.42% identified as similar to the template, and 98.39% favored region. So the results of modeling the protein structure of the three target proteins produce a structure that is identical to the template because everything is similar to the

template and the results of the quality test show that the favored region score of the three target proteins is above 80% so that the protein structure produced in this study is valid. The structure of the modeling results is displayed in the form of transparent surface, cartoon, and coloring selection based on the chain of constituent proteins in the PyMol8 software⁸. The target protein that has two chains namely A (green) and B (blue) are PTGS1 and PTGS2, while ADORA2A has only one chain, visualizing the results of modeling also displays the results of the Ramachandran plot (Figure 3).




Figure 3. Results of protein modeling and Ramachandran plots. (A) PTGS1, (B) PTGS2, and (C) ADORA2A.

Conclusion

In sum, the aspirin-caffeine ligand complex contained in KB1 has the potential as an antiinflammatory agent in the human body via the molecular mechanism of binding and inhibiting the biological activity of proinflammatory proteins, i.e. PTGS1, PTGS2, and ADOR2A.

Conflict of Interest : The authors declare that they have no conflict of interest.

Source of Funding : This study was supported by the Mandat Research Grant Universitas Airlangga (HRMUA).

Acknowledgements : We thank EJA – Professional Translation Services for editing the manuscript.

Ethical Approval: Ethical approval is not required for this study.

References

1. Jayanti EG, Subagio S. *Balur* and improving quality of life. *Journal of Tropical Life Science*. 2016; 6(1): 35-40.
2. Rivera-Oliver M, Díaz-Ríos M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. *Life Sciences*. 2014; 101(1-2):

- 1-9.
3. Ansori ANM, Susilo RJK, Hayaza S, *et al.* Renoprotection by *Garcinia mangostana* L. pericarp extract in streptozotocin-induced diabetic mice. *Iraqi Journal of Veterinary Science*. 2019; 33(1): 13-19.
4. Fadholly A, Ansori ANM, Jayanti S, *et al.* Cytotoxic effect of *Allium cepa* L. extract on human colon cancer (WiDr) cells: *in vitro* study. *Research Journal of Pharmacy and Technology*. 2019; 12(7): 3483-3486.
5. Kirthi V, Derry S, Moore RA, *et al.* Aspirin with or without an antiemetic for acute migraine headaches in adults. *The Cochrane Database of Systematic Reviews*. 2010; 4: CD008041.
6. Ponnoth DS, Jamal Mustafa S. Adenosine receptors and vascular inflammation. *Biochimica et Biophysica Acta*. 2011; 1808(5): 1429-1434.
7. Stankov SV. Definition of inflammation, causes of inflammation and possible anti-inflammatory strategies. *The Open Inflammation Journal*, 2012; 5: 1-9.
8. Susanto H, Kharisma VD, Listyorini D, *et al.* Effectivity of black tea polyphenol in adipogenesis related IGF-1 and its receptor pathway through *in silico* based study. *Journal of Physics: Conference Series*. 2018; 1093: 012037.
9. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discovery Today: Technologies*. 2004; 1(4): 337-341.
10. Jayaram B, Singh T, Mukherjee G, *et al.* Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. *BMC Bioinformatics*. 2012; 13 Suppl 17(Suppl 17): S7.
11. Kuhn M, von Mering C, Campillos M, *et al.* STITCH: interaction networks of chemicals and proteins. *Nucleic Acids Research*. 2008; 36(Database issue): D684-D688.
12. Adianingsih OR, Kharisma VD. Study of B cell epitope conserved region of the Zika virus envelope glycoprotein to develop multi-strain vaccine. *Journal of Applied Pharmaceutical Science*. 2019; 9(01): 98-103.
13. Hollingsworth SA, Karplus PA. A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins. *Biomolecular Concepts*. 2010; 1(3-4): 271-283.
14. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. *Journal of Lipid Research*. 2009; 50 Suppl(Suppl): S29-34.S29-34.
15. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. *Journal of Medicinal Chemistry*. 2007; 50(7): 1426-1441.
16. Haskó G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. *Journal of Leukocyte Biology*. 2008; 83(3): 447-455.
17. Chen JF, Eltzhig HK, Fredholm BB. Adenosine receptors as drug targets--what are the challenges? *Nat Rev Drug Discov*. 2013; 12(4): 265-286.
18. Szklarczyk D, Santos A, von Mering C, *et al.* STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. 2016. 44(D1): D380-D384.
19. Schwede T, Kopp J, Guex N, *et al.* SWISS-MODEL: An automated protein homology-modeling server. *Nucleic Acids Research*. 2003; 31(13): 3381-3385.
20. Bienert S, Waterhouse A, de Beer TA, *et al.* The SWISS-MODEL Repository-new features and functionality. *Nucleic Acids Research*. 2017; 45(D1): D313-D319.